Source: Eur Respir Rev 2012; 21: 57-65
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A.. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012; 21: 57-65

Member's Comments

No comment yet.

Related content which might interest you: Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects Source: Eur Respir J 2005; 26: 1086-1091 Year: 2005 Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia Source: Eur Respir J 2010; 36: 1073-1079 Year: 2010 Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 Clinical effectiveness of pneumococcal vaccination against nonbacteremic pneumonia in people over 50 years Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008 Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013) Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Invasive pneumococcal disease (IPN) and pneumococcal vaccination in our setting Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough. Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Source: Eur Respir J 2010; 36: 608-614 Year: 2010 A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany Source: Eur Respir J, 59 (2) 2102432; 10.1183/13993003.02432-2021 Year: 2022 Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes Source: Eur Respir J 2014; 43: 545-553 Year: 2013 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Influenza vaccination is associated with reduced severity of community-acquired pneumonia Source: Eur Respir J 2011; 37: 147-153 Year: 2011 Influenza and pneumococcal vaccination in patients with COPD Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Should pneumococcal vaccines be used to prevent LRTI? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018